New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
14:13 EDTACT, TEVAActavis wins part of appeals court ruling against Teva unit
A U.S. appeals court reversed part of a ruling in favor of Watson Pharmaceuticals, now known as Actavis (ACT), over Teva's (TEVA) Cephalon unit in a patent lawsuit over the cancer drug Fendora. The appeals court upheld a lower court's ruling that a generic version made by Actavis did not copy the way the drug is delivered into the system through a mucous membrane. The appeals court did overturn a lower court ruling that the patents are invalid, however.Reference Link
News For ACT;TEVA From The Last 14 Days
Check below for free stories on ACT;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
July 16, 2014
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
July 15, 2014
11:13 EDTTEVAPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
July 14, 2014
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
July 11, 2014
16:31 EDTACTActavis confirms generic Diclegis patent challenge
Subscribe for More Information
July 9, 2014
07:15 EDTTEVATeva, others fined $583.4M by EU regulators, Reuters says
Subscribe for More Information
06:49 EDTACT, TEVAGeneric drug prices have risen significantly, NY Times says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use